YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
AbbVie ABBV announced that the FDA has granted two Breakthrough Therapy designations (BTDs) to its investigational next-generation antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A; ABBV-400), for two different types of canc…
Ultragenyx Pharmaceutical RARE has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The transaction is expected to provide the rare-disease drugmaker with a meaningful inf…
CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene ed…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agilon Health (AGL) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to f…
In the latest close session, CRISPR Therapeutics AG (CRSP) was down 5.82% at $54.00. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq…
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect…
CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CR…
CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past m…
[Nvidia Corporation building in Taipei, Taiwan.] BING-JHEN HONG This week, insider transactions were seen across major technology companies, including Nvidia (NVDA [https://seekingalpha.com/symbol/NVDA]), Oracle (ORCL [https://seekingalpha…
CRISPR Therapeutics AG (CRSP) closed at $54.23 in the latest trading session, marking a -2.64% move from the prior day. This change lagged the S&P 500's daily gain of 0.51%. At the same time, the Dow added 0.93%, and the tech-heavy Nasdaq…
CRISPR Therapeutics has seen its share price move around over the years, leaving investors with a mixed track record and a lot of questions about what the current US$55.70 level really reflects. The key issue now is whether that price line…
Novartis AG's (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiova…
This article first appeared on GuruFocus. Gene-editing stocks fell Wednesday after Anthropic's Claude AI model identified an enzyme system with characteristics similar to technology used to alter DNA. Beam Therapeutics (BEAM), CRISPR Thera…
Q2 13F filings show that billionaire Ken Fisher's Fisher Asset Management opened new positions in CRISPR Therapeutics (NASDAQ: CRSP) and Coinbase Global (NASDAQ: COIN). Fisher's fund bought 77,960 CRISPR Therapeutics shares valued at about…
Company Logo Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy MarketAutol…
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.03, marking a +1.2% move from the previous day. Meanwhile, the Dow lost 0.36%, and the Nasdaq, a tech-heavy index, added 0.45%. Heading into today, shares of the co…
It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP). This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors…
Company Logo The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV…
Intellia Therapeutics NTLA leverages its proprietary technologies and expertise, including CRISPR-based gene-editing technologies, oligonucleotides and lipid nanoparticles (LNPs), to develop novel, first-in-class therapeutic candidates. Th…
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base. Continue Reading
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect…
CRISPR Therapeutics (CRSP) is drawing fresh attention as investors digest management's recent comments on faster CASGEVY uptake and prepare for an earnings update that is expected to show higher revenue and a smaller loss. CRISPR Therapeut…
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.80, moving -2.19% from the previous trading session. This move lagged the S&P 500's daily loss of 0.45%. Meanwhile, the Dow experienced a drop of 0.63%, and the techno…
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this company have r…
This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical doll…
Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when she sees a new opportunity. That's what she did last week, pouring $27.9 million into Meta Platforms (META) as the company pushes deeper into AI. Last…
Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is…
Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amgen…
Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate d…
The healthcare sector is evolving as traditional drug development meets revolutionary gene editing. Investors are now choosing between Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) for their medical portfolios. Ax…
Given that the beginning of 2027 is now less than four months away, it wouldn't be wrong to begin positioning your portfolio for the coming year. To this end, here's a closer look at two pharmaceutical stocks, each with a handful of develo…
Cathie Wood, chief of Ark Investment Management, likes to chase momentum in her favorite tech bets. This week, she's buying $6.5 million of Cerebras stock as the AI chip stock surges. Last year, the flagship Ark Innovation ETF gained 35.49…
A month has gone by since the last earnings report for Rocket Pharmaceuticals (RCKT). Shares have added about 6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release…
Pioneering gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) was a well-performing biotech stock in August. Its shares were hot in the hot month, zooming almost 19% higher thanks to a solid quarterly earnings report and business upda…
An updated edition of the July 20, 2026, article. Genomics is a comprehensive study of genomes (an organism's complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this area have heightened interest from pharmaceutic…